University of California San Francisco
Give to UCSF
<p>San Francisco General Hospital's internationally renowned Ward 86, one of the oldest and largest HIV/AIDS clinics in the United States, has from the start of the epidemic led efforts to understand HIV and develop treatments that make it possible for patients to manage the disease.</p>
<p>Laurence Huang, MD, a professor of medicine in the HIV/AIDS Division, will give a lecture titled “30 Years of PCP in HIV/AIDS: Past, Present, Future” at San Francisco General Hospital from noon until 1 p.m. on Tuesday, June 7.</p>
<p>Thanks to life-saving treatment, in a few years most people in the United States living with the AIDS virus, HIV, will be more than 50 years old. But even among the successfully treated, HIV, is associated with chronic inflammation, and higher rates of chronic diseases of aging. Inflammation may be a driver of aging, some scientists believe, and HIV patients may be vulnerable to accelerated aging as a result.</p>
<p>Preventing transmission to partners or children is key to this curbing the HIV/AIDS epidemic and researchers report t exciting new tools and tactics employed in the now 30-year war against the disease.</p>
<p>For the past 30 years, UCSF has been a leader in AIDS basic and clinical research, patient care, policy development and community and global outreach, efforts that were among the first in the nation in response to the epidemic. </p>
<p>As one of the preeminent biomedical education and health sciences research institutions in the world, UCSF emerged early as a pioneer in the fight against AIDS. Today, three decades later, UCSF is working on multiple fronts to prevent, treat and stop the spread of the disease that has killed 33 million people worldwide.</p>
The nation’s system of freeing some terminally ill prisoners on grounds of compassionate release is so riddled with medical flaws and procedural barriers that many potentially medically eligible inmates are dying behind bars, say UCSF researchers in a new study.
The ongoing controversy surrounding the safety of using TASER® electrical stun guns took a new turn today when a team of cardiologists at the University of California, San Francisco announced findings suggesting that much of the current TASER®-related safety research may be biased due to ties to the devices’ manufacturer, TASER International, Inc.
<p>UCSF's basic research over nearly two decades has led to the first novel antitoxin to treat botulism in nearly a century – becoming the first recombinant human therapy to target one of the most dangerous substances known to man and offering a new defense against bioterrorism.</p>